Fosun Pharma Valuation Multiples

Fosun Pharma Overview

About Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

Founded

1995

HQ

Employees

40.6K

Website

fosunpharma.com

Sectors

BiopharmaceuticalsBioTechHealthTech

Financials (LTM)

Revenue: $6B

EBITDA: $992M

EV

$13B

Valuation Multiples

Multiples.vc

Start free trial

Fosun Pharma Financials

Fosun Pharma reported last 12-month revenue of $6B and EBITDA of $992M.

In the same LTM period, Fosun Pharma generated $3B in gross profit, $992M in EBITDA, and $515M in net income.

Fosun Pharma P&L

In the most recent fiscal year, Fosun Pharma reported revenue of $6B and EBITDA of $1B.

Fosun Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Fosun Pharma Stock Performance

Fosun Pharma has current market cap of $10B, and enterprise value of $13B.

Fosun Pharma's stock price is $3.57.

Fosun Pharma Valuation Multiples

Fosun Pharma trades at 2.1x EV/Revenue multiple, and 13.0x EV/EBITDA.

Fosun Pharma Financial Valuation Multiples

As of April 18, 2026, Fosun Pharma has market cap of $10B and EV of $13B.

Equity research analysts estimate Fosun Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Fosun Pharma has a P/E ratio of 18.5x.

Fosun Pharma Margins & Growth Rates

Fosun Pharma's revenue in the last 12 month grew by 5%.

Fosun Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Fosun Pharma's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fosun Pharma's rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Fosun Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Fosun Pharma M&A Activity

Fosun Pharma acquired XXX companies to date.

Last acquisition by Fosun Pharma was on XXXXXXXX, XXXXX. Fosun Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Fosun Pharma Investment Activity

Fosun Pharma invested in XXX companies to date.

Fosun Pharma made its latest investment on XXXXXXXX, XXXXX. Fosun Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).